U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07623577) titled 'Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases' on Dec. 18, 2025.
Brief Summary: This is a single-arm, multi-center phase II study to evaluate the safety and efficacy Sacituzumab Tirumotecan (Sac-TMT) plus bevacizumab in triple-negative breast cancer patients with brain metastases. Twenty-four participants are planned to be enrolled. The eligible patients should have histologically or cytologically confirmed TNBC with BM.
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
TNBC
Brain Metastasis
Intervention:
DRUG: Sacituzumab Tirumotecan (Sac-TMT)
Eligible patients will receive a dosage of sac-TMT ...